Surgical Oncology — Sarcoma
UC Davis Comprehensive Cancer Center offers comprehensive, multidisciplinary care for young and adult patients with bone and soft-tissue sarcomas — cancers that affect bone, muscle, cartilage, blood vessels and other connective tissues in the body. Sarcoma treatment at UC Davis Cancer Center is aimed at preservation of critical functions, prevention of disease recurrence and optimization of quality of life.
Your team of cancer specialists will include experts in medical oncology, surgical and orthopaedic oncology, plastic surgery, and vascular surgery. Pre-operative and post-operative patient care also requires close coordination with radiation oncology, medical oncology and radiology.
Soft tissue sarcomas represent challenging malignancies for which care is best delivered at specialized, high-volume referral centers, such as UC Davis Comprehensive Cancer Center. Patients frequently have large tumors that are technically challenging to remove with surgery, and the pre- and post-operative care for these patients requires careful coordination among multiple disciplines.
UC Davis Comprehensive Cancer Center delivers high quality care to patients with sarcoma from Northern California, Southern California, Western Nevada and Oregon.
Surgery is the most common treatment for adult soft tissue sarcoma, and sometimes the only treatment needed. Specific surgical procedures may include:
Wide local excision: Removal of the tumor along with a cuff or “margin” of normal tissue around it.
Limb-sparing surgery: This approach involves a more extensive removal of the tumor and surrounding soft tissue in an arm or leg, but remains able to avoid amputation, so the use and appearance of the limb are preserved. Critical structures such as nerves, blood vessels, and bone may be removed and replaced with a graft using tissue and bone taken from another part of the patient's body, or with artificial implants designed to adapt to the body.
Amputation: Surgery to remove part or all of a limb or appendage, such as an arm or leg. Since survival rates are comparable when limb-sparing surgery is combined with radiotherapy, as compared to amputation, most specialized centers currently reserve amputation for rare cases of sarcoma (about 3-5 percent) where tumors are very advanced and it is not possible to perform a complete tumor resection without severely compromising limb function.
Radiation therapy or chemotherapy: These may be given before (neoadjuvant therapy) or after (adjuvant therapy) surgery to remove the tumor. When given before surgery, the therapy will shrink the tumor, reducing the amount of tissue that needs to be removed during surgery. When given after surgery, radiation therapy or chemotherapy will kill any remaining cancer cells.
Radiation therapy: This treatment uses high-energy X-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
- External radiation therapy uses a machine outside the body to send radiation toward the cancer. One type of therapy, called fast neutron radiation therapy, aims neutrons (tiny, invisible particles) at the cancer cells to kill them. Using higher-energy radiation than X-ray radiation therapy allows the same amount of radiation to be given in fewer treatments.
- Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters, which are placed directly into or near the cancer.
Chemotherapy: This treatment uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the spinal column, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).
Targeted therapy: This treatment uses drugs or other substances to find and attack specific cancer cells without harming normal cells. Imatinib (Gleevec) is a type of targeted therapy called a tyrosine kinase inhibitor used for abdominal tumors known as GI stromal tumors (GISTs). It finds and blocks an abnormal protein on cancer cells that causes them to divide and grow.
The close collaboration among our doctors and research scientists means that new drugs and treatments developed in the laboratory can quickly move to the clinic, offering our sarcoma patients immediate access to the latest therapies.
UC Davis Comprehensive Cancer Center has a number of sarcoma clinical trials currently recruiting including:
"Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma".
VIEW STUDY DETAILS
"Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)".
VIEW STUDY DETAILS
Tseng W, Martinez SR, Tamurian RM, Borys D, Canter RJ. Histologic Type Predicts Survival in Patients with Retroperitoneal Soft-Tissue Sarcoma. Journal of Surgical Research. 2010 Sep 16.
Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J, Mak W, Monsky WL, Borys D. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft-tissue sarcoma. Annals of Surgical Oncology. 2010 Oct; 17(10):2578-84.
Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ, Robbins AS. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. Journal of the American College of Surgeons. 2010 Feb; 210(2):191-198.e2.
Harms NJ, Naderi S, Borys D, Bold RJ, Canter RJ. Complex diaphragm reconstruction using dermal collagen matrix after multivisceral resection of retroperitoneal sarcoma. Journal of Thoracic and Cardiovascular Surgery. 2010 Apr; 139(4):1081-3.
Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clinical Cancer Research. 2008 Dec 15; 14(24):8191-7.
Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF. Why do patients with low-grade soft-tissue sarcoma die? Annals of Surgical Oncology. 2008 Dec; 15(12):3550-60.
Canter RJ, Qin LX, Downey RJ, Brennan MF, Singer S, Maki RG. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis. Cancer. 2007 Nov 1; 110(9):2050-60.
Oncologists Specializing in Sarcoma
Vijay P. Khatri, M.D.
Professor of Surgical Oncology
Director of Department of Surgery Faculty Development and Mentoring
Robert Canter, M.D.
Assistant Professor of Surgery
Orthopaedic Oncology Surgery
Robert John Steffner, M.D.
Chief of Orthopaedic Oncology
Hematology and Oncology
Scott Christensen, M.D.
Professor of Internal Medicine, Hematology and Oncology
Associate Director, Hospice Program
Medical Director, Cancer Care Network
Pediatric Hematology and Oncology
Jonathan M. Ducore, M.D., M.P.H.
Professor of Pediatrics
Chief of Pediatric Hematology and Oncology
Medical Director of the Pediatric Infusion Center
Co-Director of the Hemophilia Treatment Center
Noriko Satake, M.D.
Assistant Professor of Pediatrics
Janet Yoon, M.D.
Assistant Professor of Pediatrics
Theodore Zwerdling, M.D.
Associate Professor of Pediatrics